Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton

EF Hutton notes that Citius Pharmaceuticals (CTXR) has been under pressure since the company spun-out Lymphir into Citius Oncology (CTOR) and sees “no particular reason,” adding that “perhaps investors fear a reverse split,” but telling investors that the firm has “confidence that is not in the cards.” The firm, which remains bullish on Citius for their 90% ownership in Citius Oncology and for Mino-Lok, maintains a Buy rating and $6 price target on Citius shares and views the weakness in shares as an opportunity.